X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (178) 178
index medicus (166) 166
hematology (106) 106
oncology (95) 95
male (81) 81
female (71) 71
middle aged (70) 70
aged (65) 65
adult (61) 61
animals (43) 43
aged, 80 and over (40) 40
chronic myelogenous leukemia (40) 40
leukemia (40) 40
cancer (37) 37
imatinib mesylate (35) 35
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (35) 35
stem cells (35) 35
research (34) 34
chronic myeloid-leukemia (30) 30
chronic myeloid leukemia (29) 29
adolescent (28) 28
mutation (28) 28
telomere (27) 27
dasatinib (26) 26
mice (26) 26
treatment outcome (26) 26
analysis (25) 25
hemic and lymphatic diseases (25) 25
cell line, tumor (24) 24
imatinib (24) 24
expression (23) 23
antineoplastic agents - therapeutic use (22) 22
cell biology (22) 22
abridged index medicus (21) 21
benzamides (21) 21
prognosis (21) 21
cells (20) 20
leukemia, myelogenous, chronic, bcr-abl positive - pathology (20) 20
protein kinase inhibitors - therapeutic use (20) 20
pyrimidines - therapeutic use (20) 20
young adult (20) 20
bcr-abl (19) 19
telomerase (19) 19
tyrosine (19) 19
bone-marrow (18) 18
cell proliferation (18) 18
hematopoietic stem cells (18) 18
in situ hybridization, fluorescence (18) 18
medicine & public health (18) 18
aniline compounds - therapeutic use (17) 17
antineoplastic agents - pharmacology (17) 17
follow-up studies (17) 17
in-vitro (17) 17
leukemia, myelogenous, chronic, bcr-abl positive - genetics (17) 17
nitriles - therapeutic use (17) 17
progenitor cells (17) 17
quinolines - therapeutic use (17) 17
patients (16) 16
piperazines - pharmacology (16) 16
piperazines - therapeutic use (16) 16
pyrimidines - pharmacology (16) 16
telomeres (16) 16
therapy (16) 16
tyrosine kinase inhibitor (16) 16
aniline compounds - adverse effects (15) 15
antineoplastic agents - adverse effects (15) 15
drug resistance, neoplasm (15) 15
kinases (15) 15
length (15) 15
multidisciplinary sciences (15) 15
nilotinib (15) 15
nitriles - adverse effects (15) 15
protein kinase inhibitors - adverse effects (15) 15
quinolines - adverse effects (15) 15
cancer research (14) 14
care and treatment (14) 14
cells, cultured (14) 14
flow cytometry (14) 14
gene expression (14) 14
myeloid leukemia (14) 14
protein kinase inhibitors - administration & dosage (14) 14
proteins (14) 14
stem-cells (14) 14
transplantation (14) 14
bosutinib (13) 13
cml (13) 13
cytogenetic responses (13) 13
fusion proteins, bcr-abl - genetics (13) 13
genetic aspects (13) 13
medicine (13) 13
protein-tyrosine kinases - antagonists & inhibitors (13) 13
research article (13) 13
survival (13) 13
telomerase - metabolism (13) 13
age (12) 12
bone marrow (12) 12
disease (12) 12
flow-cytometry (12) 12
pyrimidines - adverse effects (12) 12
telomere - metabolism (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 11/2017, Volume 142, Issue 23, pp. 1744 - 1749
Abstract Reasons for leukopenia can be numerous. To get close to the diagnosis it’s always useful to check previous blood counts of the patient to get a... 
Dossier
Journal Article
Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 11/2017, Volume 142, Issue 23, pp. 1744 - 1749
Journal Article
Klinikarzt, ISSN 0341-2350, 2018, Volume 47, Issue 9, pp. 398 - 402
Journal Article
Journal Article
ISSN 1179-2736, 2018
Journal Article
Blood, ISSN 0006-4971, 04/2012, Volume 119, Issue 15, pp. 3403 - 3412
Journal Article
Blood, ISSN 0006-4971, 10/2011, Volume 118, Issue 17, pp. 4567 - 4576
Journal Article
Cancer, ISSN 0008-543X, 10/2012, Volume 118, Issue 20, pp. 5183 - 5183
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2015, Volume 168, Issue 1, pp. 69 - 81
Bosutinib is an oral, dual SRC / ABL 1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia ( CML ). We assessed the efficacy and... 
BCR‐ABL1 | CML | tyrosine kinase inhibitor | bosutinib | chronic myeloid leukaemia | Chronic myeloid leukaemia | Tyrosine kinase inhibitor | Bosutinib | BCR-ABL1 | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | MOLECULAR RESPONSES | DASATINIB | NILOTINIB | RESISTANT | INTERFERON-ALPHA | IN-VITRO | PATIENTS RECEIVING IMATINIB | INHIBITOR | HEMATOLOGY | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Odds Ratio | Benzamides - adverse effects | Aniline Compounds - administration & dosage | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Index Medicus | Haematological Malignancy
Journal Article
Blood, ISSN 0006-4971, 02/2014, Volume 123, Issue 9, pp. 1309 - 1318
Journal Article
Nature Medicine, ISSN 1078-8956, 03/2016, Volume 22, Issue 3, pp. 288 - 297
Impaired erythropoiesis in the deletion 5q (del(5q)) subtype of myelodysplastic syndrome (MDS) has been linked to heterozygous deletion of RPS14; which encodes... 
MEDICINE, RESEARCH & EXPERIMENTAL | HUMAN 5Q-SYNDROME | BIOCHEMISTRY & MOLECULAR BIOLOGY | BONE-MARROW | DELETION 5Q | RISK MYELODYSPLASTIC SYNDROME | CELL BIOLOGY | HEMATOPOIETIC STEM-CELLS | MOUSE MODEL | DIAMOND-BLACKFAN ANEMIA | MYELOID-LEUKEMIA | SUPPRESSOR-CELLS | UP-REGULATION | Immunohistochemistry | Calgranulin A - metabolism | Humans | Immunity, Innate - genetics | Calgranulin A - genetics | Tumor Suppressor Protein p53 - genetics | Anemia - genetics | Flow Cytometry | Mass Spectrometry | Calgranulin B - genetics | Megakaryocytes | Cytokines - immunology | Disease Models, Animal | Erythropoiesis - genetics | Haploinsufficiency - genetics | Anemia - immunology | Ribosomal Proteins - genetics | In Situ Hybridization, Fluorescence | Blotting, Western | Mice, Knockout | Immunity, Innate - immunology | Microscopy, Confocal | Animals | Bone Marrow - pathology | Fluorescent Antibody Technique | Erythroid Precursor Cells - metabolism | Mice | Myelodysplastic Syndromes - genetics | In Vitro Techniques | Myelodysplastic Syndromes - pathology | Myelodysplastic Syndromes - immunology | Erythropoiesis - immunology | Hematopoietic Stem Cells | Erythropoiesis | Physiological aspects | Genetic aspects | Research | Cell differentiation | Hematopoietic stem cells | Proteins | Gene expression | Anemia | Erythrocytes | Apoptosis | Immune system | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2018, Volume 36, Issue 3, pp. 231 - 237
Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) resistant... 
TREATMENT-FREE REMISSION | 24-MONTH FOLLOW-UP | ONCOLOGY | SAFETY | RESISTANCE | INTOLERANCE | DASATINIB | OUTCOMES | LONG-TERM EFFICACY | Index Medicus | ORIGINAL REPORTS
Journal Article